Xeris Biopharma (NASDAQ:XERS) Stock Rating Raised to “Strong-Buy” at Wall Street Zen

Xeris Biopharma (NASDAQ:XERS) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued reports about the company. Leerink Partners boosted their price target on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Piper Sandler restated a “neutral” rating and set a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. HC Wainwright lifted their price objective on shares of Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a report on Friday. Barclays upped their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 6th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a report on Friday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Xeris Biopharma has an average rating of “Moderate Buy” and an average target price of $16.20.

Xeris Biopharma Trading Up 16.2%

NASDAQ XERS opened at $15.20 on Friday. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The stock’s 50-day moving average is $9.62 and its 200-day moving average is $7.62. The firm has a market cap of $2.77 billion, a P/E ratio of -303.94 and a beta of 0.61. Xeris Biopharma has a one year low of $5.25 and a one year high of $15.21.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The company had revenue of $107.23 million for the quarter, compared to analyst estimates of $101.68 million. Sell-side analysts anticipate that Xeris Biopharma will post 0.07 earnings per share for the current fiscal year.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Following the transaction, the insider directly owned 1,614,208 shares in the company, valued at approximately $16,142,080. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $255,750.00. Following the sale, the insider directly owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. This represents a 2.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 173,332 shares of company stock valued at $1,721,471 over the last 90 days. Insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds have recently modified their holdings of XERS. BlackRock Inc. acquired a new stake in Xeris Biopharma during the second quarter worth about $115,042,000. Legal & General Group Plc bought a new stake in shares of Xeris Biopharma in the second quarter valued at about $15,941,000. Parkman Healthcare Partners LLC bought a new position in Xeris Biopharma in the 2nd quarter valued at $14,316,000. Bank of America Corp DE bought a new position in shares of Xeris Biopharma during the 2nd quarter valued at about $11,065,000. Finally, Vilga Financial Planning LLC acquired a new position in shares of Xeris Biopharma during the 3rd quarter worth about $10,134,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

More Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.